Arteriocyte Medical Technologies: Business Overview, Financials & Competitive Analysis
Arteriocyte Medical Technologies scores 4/10 on the AskCyborg Cyborg Score (Weak). Legacy regenerative medicine player with proven technology but unclear current status and market relevance post-acquisition. The company was acquired by ISTO Technologies in October 2016 and now operates as Isto Biologics. Recent activity and current market position are unclear from available public sources. Limited financial and operational transparency post-acquisition.
What is Arteriocyte Medical Technologies's industry? Arteriocyte Medical Technologies (arteriocyte.com) operates in Medical Devices. AskCyborg classifies Arteriocyte Medical Technologies under Medical Devices in its company registry.
Arteriocyte Medical Technologies is a regenerative medicine company focused on stem cell and tissue engineering-based therapies. The company develops point-of-care medical devices and cellular concentrates for orthope...
Cyborg Score thesis
Legacy regenerative medicine player with proven technology but unclear current status and market relevance...
Read the full analyst-debate transcript →Get the Latest Arteriocyte Medical Technologies Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeArteriocyte Medical Technologies Overview
Pro stress-test →Arteriocyte Medical Technologies is a regenerative medicine company focused on stem cell and tissue engineering-based therapies. The company develops point-of-care medical devices and cellular concentrates for orthopedic, cardiac, and vascular applications.
Strategic Profile
Pro stress-test →Arteriocyte pioneered bedside cell therapy systems including the Magellan platform for rapid production of platelet-rich plasma and bone marrow-derived cellular concentrates. The company has pursued clinical development in orthopedic trauma and critical limb ischemia with partnerships including the U.S. Army Institute of Surgical Research.
Competitive Landscape
Pro stress-test →Arteriocyte competes in the regenerative medicine and point-of-care cell therapy device space. Competitors include broader regenerative medicine companies and orthopedic implant manufacturers developing cell-based solutions.
Industry Context
Arteriocyte Medical Technologies operates in Medical Devices.
Key facts
Founded: 2004 · Headquarters: Cleveland, US · Employees: 51-100 · Revenue: N/A · Market cap: N/A